
News|Articles|December 3, 2025
Accelerate Cell Line Development with GPEx® Lightning: Speed, Stability, and Industry-Leading Titers
Author(s)Catalent
Catalent’s GPEx® Lightning platform delivers stable, high-yield cell lines with unmatched speed—achieving titers up to 15g/L for mAbs and 11g/L for bispecifics. With 25-day pool generation and up to 12 weeks saved on development timelines, this offering sheet outlines key performance metrics and benefits that make GPEx® Lightning a game-changer for biologics developers.
Trending on Pharmaceutical Technology
1
What FDA's AI Warning Letter Tells Us About GMP Accountability
2
Why Are Drugmakers Racing to Acquire ADC Payload Platforms?
3
The Evolving World of Counterfeit Drugs...Where Does Serialization Fit?
4
Anti-Counterfeit and Security Solutions for Secondary Packaging
5